DE69826124D1 - Verabreichung der nukleinsäure in den quergestreiften muskel - Google Patents

Verabreichung der nukleinsäure in den quergestreiften muskel

Info

Publication number
DE69826124D1
DE69826124D1 DE69826124T DE69826124T DE69826124D1 DE 69826124 D1 DE69826124 D1 DE 69826124D1 DE 69826124 T DE69826124 T DE 69826124T DE 69826124 T DE69826124 T DE 69826124T DE 69826124 D1 DE69826124 D1 DE 69826124D1
Authority
DE
Germany
Prior art keywords
nucleic acid
molecule
administration
muscle cell
sup
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69826124T
Other languages
English (en)
Other versions
DE69826124T2 (de
DE69826124T3 (de
Inventor
Michel Bureau
Lluis Mit
Daniel Scherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26233648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69826124(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9708233A external-priority patent/FR2765242B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Gustave Roussy (IGR), Aventis Pharma SA filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE69826124D1 publication Critical patent/DE69826124D1/de
Publication of DE69826124T2 publication Critical patent/DE69826124T2/de
Application granted granted Critical
Publication of DE69826124T3 publication Critical patent/DE69826124T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0412—Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • A61N1/0416—Anode and cathode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69826124T 1997-06-30 1998-06-30 Verabreichung der nukleinsäure in den quergestreiften muskel Expired - Lifetime DE69826124T3 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9708233A FR2765242B1 (fr) 1997-06-30 1997-06-30 Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
FR9708233 1997-06-30
US6748897P 1997-12-01 1997-12-01
US67488P 1997-12-01
PCT/FR1998/001400 WO1999001158A1 (fr) 1997-06-30 1998-06-30 Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede

Publications (3)

Publication Number Publication Date
DE69826124D1 true DE69826124D1 (de) 2004-10-14
DE69826124T2 DE69826124T2 (de) 2005-09-15
DE69826124T3 DE69826124T3 (de) 2007-10-11

Family

ID=26233648

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69826124T Expired - Lifetime DE69826124T3 (de) 1997-06-30 1998-06-30 Verabreichung der nukleinsäure in den quergestreiften muskel

Country Status (16)

Country Link
US (1) US6939862B2 (de)
EP (1) EP0991426B2 (de)
JP (1) JP2002507985A (de)
KR (1) KR20010020571A (de)
CN (1) CN1261807A (de)
AT (1) ATE275423T1 (de)
AU (1) AU8444798A (de)
BR (1) BR9810369A (de)
CA (1) CA2294793A1 (de)
CZ (1) CZ299473B6 (de)
DE (1) DE69826124T3 (de)
HU (1) HUP0004589A3 (de)
IL (1) IL133710A0 (de)
NO (1) NO328102B1 (de)
PL (1) PL337583A1 (de)
WO (1) WO1999001158A1 (de)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL337584A1 (en) * 1997-06-30 2000-08-28 Rhone Poulenc Rorer Sa Improved method of transferring nucleic acid to eucariotic cells of multiple-cell organisms and connection enabling accomplishment of this method
US20090239940A1 (en) * 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
US6800484B2 (en) 1998-06-24 2004-10-05 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
US6678556B1 (en) * 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US7922709B2 (en) 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
AU783432B2 (en) * 1999-06-25 2005-10-27 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
CA2402530C (en) 2000-03-13 2014-01-14 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with cd99
IL151348A0 (en) 2000-04-13 2003-04-10 Univ Rockefeller Enhancement of antibody-mediated immune responses
CA2409603A1 (en) 2000-05-22 2001-11-29 Merck & Company, Inc. System and method for assessing the performance of a pharmaceutical agent delivery system
EP1353723A2 (de) 2000-11-17 2003-10-22 Gendel Limited Entfernung von zellen mit combiniertem elektrischem feld und ultraschall therapie
US6821274B2 (en) 2001-03-07 2004-11-23 Gendel Ltd. Ultrasound therapy for selective cell ablation
DK1355918T5 (da) 2000-12-28 2012-02-20 Wyeth Llc Rekombinant beskyttelsesprotein af streptococcus pneumoniae
CA2441476A1 (en) 2001-03-02 2002-09-12 The Rockefeller University Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
US20040023910A1 (en) * 2001-09-28 2004-02-05 Zhiming Zhang Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
JP2005518904A (ja) 2002-03-07 2005-06-30 マーク アンド カンパニー インコーポレイテッド 電気的刺激の側面を備えた臨床用注射器
CA2487284A1 (en) 2002-05-23 2003-12-04 Gendel Limited Ablation device
EP2316922B1 (de) 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Humaner neutraliserender Anti-IGFR Antikörper
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
WO2005023292A1 (en) 2003-09-03 2005-03-17 The General Hospital Corporation Methods of treating restenosis
JP4929159B2 (ja) 2004-04-16 2012-05-09 ヌーヴ セラピュティクス、インコーポレイテッド 画像誘導組織切除を改善するための装置
FR2880808A1 (fr) * 2005-01-20 2006-07-21 Yves Scherman Dispositif pour l'administration de principe actif aux cellules et tissus a l'aide d'electrodes de surface non invasives
US8101169B2 (en) * 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
US7923251B2 (en) * 2005-02-23 2011-04-12 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for avalanche-mediated transfer of agents into cells
RS51324B (sr) 2005-04-25 2010-12-31 Merial Ltd. Vakcine protiv nipah virusa
CN101437539B (zh) 2005-07-05 2013-10-02 康奈尔研究基金会（有限公司） 通过干扰cd99l2阻断白细胞迁出和炎症
FR2889066B1 (fr) * 2005-07-28 2007-11-09 Centre Nat Rech Scient Procede d'immunisation genetique par electrotransfert contre une toxine et antiserum susceptible d'etre obtenu par ledit procede
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
JP2009515529A (ja) 2005-11-14 2009-04-16 メリアル リミテッド 腎不全のための遺伝子療法
EP2829551B1 (de) 2006-10-19 2017-12-13 CSL Limited Hochaffine Antikörperantagonisten des Interleukin-13-Rezeptors Alpha 1
CA2666682C (en) 2006-10-19 2014-07-08 Merck & Co., Inc. Anti-il-13r.alpha.1 antibodies and their uses thereof
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008136790A1 (en) 2007-05-02 2008-11-13 Merial Limited Dna plasmids having improved expression and stability
CA2720168A1 (en) 2008-04-04 2009-10-08 David B. Weiner A composition, system and method for removal of detergents from aqueous solutions
US8093043B2 (en) 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
EP2147697A1 (de) 2008-07-21 2010-01-27 Centre National De La Recherche Scientifique-CNRS Verfahren und Vorrichtung zur Anwendung elektrischer Felder in leitfähiges Material
EP2156860A1 (de) 2008-08-20 2010-02-24 Centre National De La Recherche Scientifique-CNRS Verfahren zur Herstellung isolierter Elektroden zum Einfügen elektrischer Felder in ein leitfähiges Material
CN102203122A (zh) 2008-11-05 2011-09-28 惠氏有限责任公司 用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物
MX2011005604A (es) 2008-11-28 2011-09-01 Merial Ltd Vacuna recombinante para influenza aviar y sus usos.
EP2477659A4 (de) 2009-09-14 2014-01-15 Univ Pennsylvania Impfstoffe und immuntherapeutika mit dafür kodierenden il-15-rezeptor-alpha- und/oder nukleinsäuremolekülen sowie verfahren zu ihrer anwendung
KR20210149203A (ko) 2009-11-02 2021-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 구제역 바이러스(ｆｍｄｖ) 공통 단백질, 이를 위한 코딩 서열 및 이로부터 만들어진 백신
WO2011090708A2 (en) 2009-12-28 2011-07-28 Merial Limited Recombinant ndv antigen and uses thereof
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
AU2011213559B2 (en) 2010-02-08 2015-05-07 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
AU2011224188B2 (en) 2010-03-12 2015-01-22 Boehringer Ingelheim Animal Health USA Inc. Bluetongue virus recombinant vaccines and uses thereof
HUE052850T2 (hu) 2010-08-23 2021-05-28 Wyeth Llc Neisseria meningitidis RLP2086 antigéneket tartalmazó stabil készítmények
ES2585328T5 (es) 2010-09-10 2022-12-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
KR20180096814A (ko) 2010-09-27 2018-08-29 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 공통 항원 구성체 및 이것으로부터 만들어진 백신 및 말라리아를 치료하기 위한 이것의 사용방법
BR112013011705B1 (pt) 2010-11-12 2022-04-05 The Trustees Of The University Of Pennsylvania Antígenos de próstata de consenso, molécula de ácido nucleico quecodifica os mesmos e vacina e usos compreendendo os mesmos
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
KR20190112175A (ko) 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 항―ｎｇｆ 조성물 및 그의 용도
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
CA2826199A1 (en) 2011-01-31 2012-08-09 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
EA037377B1 (ru) 2011-02-11 2021-03-22 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Вакцина для индукции иммунного ответа на hbv
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
AU2012262740B2 (en) 2011-05-27 2017-06-01 Boehringer Ingelheim Animal Health USA Inc. Genetic vaccines against Hendra virus and Nipah virus
EP2714077B1 (de) 2011-06-01 2018-02-28 Merial, Inc. Nadellose verabreichung von prrsv-impfstoffen
ES2758713T3 (es) 2011-07-11 2020-05-06 Inovio Pharmaceuticals Inc Vacuna de ADN contra el virus de Lassa
BR112014014078A8 (pt) 2011-12-12 2021-09-28 The Trustees Of The Univ Of Pennsylvania Composições compreendendo constructos genéticos il-12 aperfeiçoados e vacinas, imunoterapêuticos e métodos de usar os mesmos
CA2858884A1 (en) 2011-12-12 2013-06-20 The Trustees Of The University Of Pennsylvania Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections
ES2866108T3 (es) 2012-02-14 2021-10-19 Boehringer Ingelheim Animal Health Usa Inc Vectores poxvirales recombinantes que expresan proteínas de la rabia y OX40 y vacunas fabricadas a partir de los mismos
ES2632429T3 (es) 2012-02-14 2017-09-13 Merial, Inc. Vacunas subunitarias de rotavirus y procedimientos para la fabricación y utilización de las mismas
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
EP3326646A1 (de) 2012-03-22 2018-05-30 Merial, Inc. Modifiziertes marek-krankheitsvirus und daraus hergestellte impfstoffe
KR20140146651A (ko) 2012-04-10 2014-12-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 인간 호흡기 합포체 바이러스 공통 항원, 핵산 컨스트럭트 및 이들로부터 제조된 백신, 및 이들을 사용하는 방법
EP4190350A1 (de) 2012-04-12 2023-06-07 The Trustees Of The University Of Pennsylvania Filovirus-konsensusantigene, nukleinsäurekonstrukte und daraus hergestellte impfstoffe sowie verfahren zur verwendung davon
MA37749B1 (fr) 2012-06-13 2017-05-31 Merial Ltd Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
JP6523174B2 (ja) 2012-12-13 2019-05-29 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｗｔ１ワクチン
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
MX2015011487A (es) 2013-03-15 2016-02-03 Univ Pennsylvania Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas.
CA2898126A1 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
DK3028048T3 (en) 2013-07-31 2019-01-21 Bioventures Llc COMPOSITIONS FOR TREATMENT AND PREVENTION OF CANCER TARGETING AGAINST TUMOR-ASSOCIATED CARBOHYDRATE ANTIGEN
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SG11201604719WA (en) 2013-12-13 2016-07-28 Univ Pennsylvania Dna antibody constructs and method of using same
JP7268958B2 (ja) 2014-12-01 2023-05-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｄｎａ抗体構築物及びその使用方法
BR112017017460A2 (pt) 2015-02-19 2018-04-10 Pfizer Inc. composições de neisseria meningitidis e métodos das mesmas
WO2017031120A1 (en) 2015-08-20 2017-02-23 Merial, Inc. Fcv recombinant vaccines and uses thereof
MA43016A (fr) 2015-09-29 2018-08-08 Merial Inc Vaccins à particules pseudo-virales (vlp) de parvovirus canin (cpv) et utilisations associées
CA3006078A1 (en) 2015-11-23 2017-06-01 Merial, Inc. Fmdv and e2 fusion proteins and uses thereof
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
JP7123800B2 (ja) 2016-02-05 2022-08-23 イノビオ ファーマシューティカルズ，インコーポレイティド がんのワクチン及びそれを用いた処置の方法
WO2017180770A1 (en) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
MX2019004499A (es) 2016-10-17 2019-11-18 Janssen Pharmaceuticals Inc Star Sistemas de replicón de virus recombinante y usos de estos.
US11845939B2 (en) 2016-12-05 2023-12-19 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3083532C (en) 2017-12-13 2023-09-05 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting prame and uses thereof
US11235044B2 (en) 2017-12-13 2022-02-01 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting MUC16 and uses thereof
KR102637862B1 (ko) 2017-12-13 2024-02-19 이노비오 파마수티컬즈, 인크. 메소텔린을 표적으로 하는 암 백신 및 이의 용도
WO2019123250A1 (en) 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
MA51311A (fr) 2017-12-19 2020-10-28 Janssen Sciences Ireland Unlimited Co Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
JP2021511318A (ja) 2018-01-19 2021-05-06 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組換えレプリコン系を使用する免疫応答の誘導および増強
WO2020254876A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Virus-like particle delivery of hepatitis b virus (hbv) vaccines
WO2020255013A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives
CA3141003A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors
WO2020255010A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
US20220233526A1 (en) 2019-06-18 2022-07-28 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
WO2020255035A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyrimidine derivatives
WO2020255019A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and a quinazoline derivative
CA3140708A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
US20220241402A1 (en) 2019-06-18 2022-08-04 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
WO2020255042A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and a pyrimidine derivative
WO2020255012A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
US20220305114A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor
WO2020255014A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Recombinant interleukin 12 construct and uses thereof
WO2020255016A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
US20220233685A1 (en) 2019-06-18 2022-07-28 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
US20220249647A1 (en) 2019-06-18 2022-08-11 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
WO2020255018A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
WO2020255022A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
US20220305107A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
AU2020295012A1 (en) 2019-06-18 2022-02-17 Janssen Sciences Ireland Unlimited Company Combination of hepatitis B virus (HBV) vaccines and anti-PD-1 or anti-PD-L1 antibody
EP3986562A1 (de) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Kombination von hepatitis-b-virus(hbv)-impfstoffen und auf hbv abzielender rnai
EP3986457A1 (de) 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Company Kohlenhydrat-nanoträger-freisetzungvon hepatitis-b-virus-(hbv)-impfstoffen
TW202114732A (zh) 2019-06-20 2021-04-16 愛爾蘭商健生科學愛爾蘭無限公司 遞送b型肝炎病毒(hbv)疫苗之脂質奈米顆粒或脂質體
IL298874A (en) 2020-06-12 2023-02-01 Univ Rochester Encoding and expression of ACE-tRNAs
TW202216190A (zh) 2020-07-08 2022-05-01 愛爾蘭商健生科學愛爾蘭無限公司 抗hbv之rna複製子疫苗
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
AU2021412833A1 (en) 2020-12-28 2023-07-06 Arcturus Therapeutics, Inc. Transcription activator-like effector nucleases (talens) targeting hbv
WO2023150753A1 (en) 2022-02-07 2023-08-10 University Of Rochester Optimized sequences for enhanced trna expression or/and nonsense mutation suppression
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4301794A (en) 1978-10-18 1981-11-24 Robert Tapper Method for iontophoretic treatment
US4411657A (en) 1980-05-19 1983-10-25 Anibal Galindo Hypodermic needle
JPS5810066A (ja) 1981-07-10 1983-01-20 株式会社アドバンス イオントフオレ−ゼ用プラスタ−構造体
US4476004A (en) 1983-04-08 1984-10-09 D.E.P. Systems, Inc. Apparatus for electrofusion of biological particles
US4441972A (en) 1983-04-08 1984-04-10 D.E.P. Systems, Inc. Apparatus for electrofusion of biological particles
US4639244A (en) 1983-05-03 1987-01-27 Nabil I. Rizk Implantable electrophoretic pump for ionic drugs and associated methods
DE3317415A1 (de) 1983-05-13 1984-11-15 Kernforschungsanlage Jülich GmbH, 5170 Jülich Kammer zur behandlung von zellen im elektrischen feld
US4622031A (en) 1983-08-18 1986-11-11 Drug Delivery Systems Inc. Indicator for electrophoretic transcutaneous drug delivery device
US4557723A (en) 1983-08-18 1985-12-10 Drug Delivery Systems Inc. Applicator for the non-invasive transcutaneous delivery of medicament
ATE198350T1 (de) 1983-10-20 2001-01-15 Univ New York State Res Found Regulierung der genexpression durch translationshemmung unter verwendung einer m-rns behindernden komplementären rns
US4578168A (en) 1984-07-27 1986-03-25 Biotronics Apparatus for fusing live cells with electric fields
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US6696420B1 (en) * 1984-11-20 2004-02-24 Institut Pasteur Adenoviral vector with a deletion in the E1A coding region expressing a hetorologous protein
US4663292A (en) 1984-12-21 1987-05-05 Wong Daniel T High-voltage biological macromolecule transfer and cell fusion system
US4702732A (en) 1984-12-24 1987-10-27 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands
AT385894B (de) 1985-10-04 1988-05-25 Basem Dr Nashef Schlauchfoermige sonde
US5049488A (en) 1985-11-08 1991-09-17 Genentech, Inc. Method and nucleic acid for the preparation of lecithin:cholesterol acyltransferase
US4695547A (en) 1986-04-02 1987-09-22 Jeffrey L. Hilliard Probe for electrofusion, electroporation, or like procedure
US6007806A (en) * 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
US5744133A (en) * 1986-08-13 1998-04-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor
FR2602790B1 (fr) 1986-08-13 1990-06-01 Transgene Sa Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
US4786277A (en) 1986-11-21 1988-11-22 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation
US5371003A (en) 1987-05-05 1994-12-06 Sandoz Ltd. Electrotransformation process
US5128257A (en) 1987-08-31 1992-07-07 Baer Bradford W Electroporation apparatus and process
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
CA1340831C (en) 1987-12-15 1999-11-30 Wayne Lyle Gerlach Ribozymes
EP0398960B1 (de) 1988-01-21 1995-12-06 Massachusetts Institute Of Technology Molekültransport durch gewebe mit der verwendung von elektroporation
US5389069A (en) 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
US5547467A (en) 1988-01-21 1996-08-20 Massachusettes Institute Of Technology Method for rapid temporal control of molecular transport across tissue
US5749847A (en) 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5119832A (en) 1989-07-11 1992-06-09 Ravi Xavier Epidural catheter with nerve stimulators
US5124259A (en) 1989-08-23 1992-06-23 Mitsui Toatsu Chemicals, Inc. Method for electroporation
US6228844B1 (en) * 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US5236413B1 (en) 1990-05-07 1996-06-18 Andrew J Feiring Method and apparatus for inducing the permeation of medication into internal tissue
US5081990A (en) 1990-05-11 1992-01-21 New York University Catheter for spinal epidural injection of drugs and measurement of evoked potentials
AU8074591A (en) 1990-06-15 1992-01-07 Cortrak Medical, Inc. Drug delivery apparatus and method
US5499971A (en) 1990-06-15 1996-03-19 Cortrak Medical, Inc. Method for iontophoretically delivering drug adjacent to a heart
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5501662A (en) 1992-05-22 1996-03-26 Genetronics, Inc. Implantable electroporation method and apparatus for drug and gene delivery
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5814603A (en) 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
JPH063783A (ja) 1992-06-19 1994-01-14 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5304120A (en) 1992-07-01 1994-04-19 Btx Inc. Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
JP3099049B2 (ja) * 1992-07-29 2000-10-16 農林水産省果樹試験場長 電気的細胞融合及び電気的核酸導入のための大量処理用電極
US5273525A (en) * 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5464386A (en) 1992-08-17 1995-11-07 Genetronics, Inc. Transdermal drug delivery by electroincorporation of vesicles
US5688233A (en) 1992-08-17 1997-11-18 Genetronics, Inc. Electronincorporation enhanced transdermal delivery of molecules
US5462520A (en) 1992-08-17 1995-10-31 Genetronics, Inc. Transsurface drug delivery by electrofusion of microbubbles to the tissue surface
US5318514A (en) 1992-08-17 1994-06-07 Btx, Inc. Applicator for the electroporation of drugs and genes into surface cells
JP3351572B2 (ja) 1992-10-05 2002-11-25 井上 聰一 イオンクロマトグラフィーによる分析体の分離・分析方法、イオンクロマトグラフィー用両荷電具備固定相及び多機能液体クロマトグラフィーによる分析体の分離・分析方法
US5468223A (en) 1992-11-30 1995-11-21 C.N.R.S. Paris Electrochemotherapy
FR2703253B1 (fr) 1993-03-30 1995-06-23 Centre Nat Rech Scient Applicateur d'impulsions electriques pour traitement de tissus biologiques.
US5993434A (en) * 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
GB9317380D0 (en) * 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
DE4341424A1 (de) 1993-12-04 1995-06-08 Bosch Gmbh Robert Kraftstoffeinspritzpumpe
IL108775A (en) 1994-02-25 2003-09-17 Univ Ramot Method for efficient incorporation of molecules into cells
JPH10511008A (ja) 1994-06-24 1998-10-27 シグナス， インコーポレイテッド 膜透過性制御のための電子電圧パルスを用いた生物学的活性因子のパルス使用送達システム
US5471884A (en) 1994-07-05 1995-12-05 Motorola, Inc. Gain-adjusting circuitry for combining two sensors to form a media isolated differential pressure sensor
IT235163Y1 (it) 1994-10-10 2000-03-31 Ideal Standard Spa Gruppo di tenuta per elementi maschio di stampi per la colatura di apparecchiature igienico-sanitarie
US5641680A (en) * 1994-11-14 1997-06-24 Zhao; Xi Gene transfer apparatus and method for using the same
US5810762A (en) 1995-04-10 1998-09-22 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
AU6855796A (en) * 1995-08-29 1997-03-19 Cbr Laboratories, Inc. In vivo electroporation of cells
FR2738842B1 (fr) 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US5944710A (en) 1996-06-24 1999-08-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
US5944726A (en) 1996-08-23 1999-08-31 Scimed Life Systems, Inc. Stent delivery system having stent securement means
US5960974A (en) 1996-10-03 1999-10-05 Advance Engineered Products Ltd. Intermodal bulk container
JPH10234366A (ja) 1997-02-26 1998-09-08 Hisamitsu Pharmaceut Co Inc エレクトロポレーション用電極及びその製法、それを用いた製剤
DK1023107T3 (da) 1997-04-03 2006-12-27 Electrofect As Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) * 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
WO1999036563A1 (en) 1998-01-14 1999-07-22 Emed Corporation Electrically mediated cellular expression
EP1100579B1 (de) * 1998-07-13 2015-09-02 Inovio Pharmaceuticals, Inc. Auf haut und muskel gerrichtete gentherapie durch ein pulsierendes elektrisches feld
US6678556B1 (en) * 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle

Also Published As

Publication number Publication date
US6939862B2 (en) 2005-09-06
NO328102B1 (no) 2009-12-07
EP0991426B2 (de) 2007-03-28
CN1261807A (zh) 2000-08-02
AU8444798A (en) 1999-01-25
BR9810369A (pt) 2000-09-05
HUP0004589A1 (hu) 2001-04-28
JP2002507985A (ja) 2002-03-12
ATE275423T1 (de) 2004-09-15
PL337583A1 (en) 2000-08-28
EP0991426B1 (de) 2004-09-08
US20030073653A1 (en) 2003-04-17
NO996542D0 (no) 1999-12-29
EP0991426A1 (de) 2000-04-12
CA2294793A1 (fr) 1999-01-14
NO996542L (no) 2000-02-17
CZ299473B6 (cs) 2008-08-06
HUP0004589A3 (en) 2003-08-28
DE69826124T2 (de) 2005-09-15
DE69826124T3 (de) 2007-10-11
WO1999001158A1 (fr) 1999-01-14
IL133710A0 (en) 2001-04-30
KR20010020571A (ko) 2001-03-15
CZ475599A3 (cs) 2000-07-12

Similar Documents

Publication Publication Date Title
DE69826124D1 (de) Verabreichung der nukleinsäure in den quergestreiften muskel
EP0796081B1 (de) Elektrophoretischer apparat und verfahren zur anwendung von therapeutischen-, kosmetischen- und farblösungen im haar
WO2001085202A3 (en) Electroporation for introduction of molecules into cells
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
EA200300381A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
DK1023107T3 (da) Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen
EA199801044A1 (ru) Модуляторы регенерации тканей
DE60007290D1 (de) Einbringen von makromolekülen in zellen
WO2001089455A3 (en) System and method for assessing the performance of a pharmaceutical agent delivery system
IT1291822B1 (it) Sistema per la defibrillazione elettrica cardiaca impiantabile con attenuazione del dolore derivante dallo shock elettrico mediante
ATE113295T1 (de) Tumornekrosefaktor, verfahren zu seiner herstellung, denselben enthaltende zusammensetzungen, dafür kodierende dns und diese dns verwendendes testverfahren.
DE69837274D1 (de) Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten
DK0559884T4 (da) Rekombinante virusvektorer til ekspression i muskelceller
UA91675C2 (ru) Формула полинуклеотидной вакцины против дыхательных паталогий и паталогий размножения свиней
HUP0004728A1 (hu) Javított eljárás nukleinsav bevitelére többsejtes eukarióta szervezet sejtjeibe és kombinált alkalmazása
IT1206311B (it) Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso.
DE69833784D1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
IT1187828B (it) Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
EP0232523A3 (en) Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins
EA199901048A1 (ru) Увеличение электрической проводимости и сокращаемости с помощью двухфазного кардиостимулятора
EA200100583A1 (ru) Композиции, содержащие лактадгерин или его варианты, и способы их использования
DE19781038T1 (de) Keratinozytenwachstumsfaktor-2-Produkte
EP0219258A3 (de) Peptid-Antagonisten von Neurokinin-B und sie enthaltende ophthalmische Lösungen
ATE309370T1 (de) Retinoid-metabolisierendes protein
PT866861E (pt) Clonagem molecular e caracterizacao de moleculas relacionadas com relaxina e com a familia dos ligandos da insulina

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: INSTITUT GUSTAVE ROUSSY, VILLEJUIF, FR